Product image of Malarone Paediatric (Proguanil Hydrochloride, Atovaquone) supplied by GNH India

Malarone Paediatric

Active Ingredient:
Proguanil Hydrochloride, Atovaquone
Origin:
EU

Malarone Paediatric (Proguanil Hydrochloride, Atovaquone)

Atovaquone/proguanil, the active ingredient in Malarone Paediatric, is an antimalarial combination presented as an oral tablet for oral use. It is used to prevent and treat malaria caused by Plasmodium falciparum in children. The combination exploits synergistic mechanisms to provide both prophylactic and therapeutic coverage in pediatric patients traveling to or residing in malaria‑endemic regions.

GNH India supplies Malarone Paediatric as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams in both public and private health sectors worldwide.

Manufacturer / TM Owner

Glaxo Wellcome Uk Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Malarone Paediatric, an antimalarial combination, is indicated for the prevention and treatment of malaria caused by Plasmodium falciparum.

  • Prevention of malaria (travel prophylaxis): Provides protective antimalarial activity for children traveling to or residing in endemic areas.
  • Treatment of acute uncomplicated malaria: Clears Plasmodium falciparum infection in pediatric patients with confirmed malaria.
  • Post‑exposure prophylaxis: Used after possible exposure to malaria‑infected mosquitoes to prevent disease onset in children.

How It Works

  • Atovaquone inhibits the mitochondrial electron transport chain of Plasmodium parasites, disrupting energy production, while proguanil is metabolised to cycloguanil, which blocks the parasite's dihydrofolate reductase enzyme, impairing folate synthesis. The dual action produces a synergistic antimalarial effect that both prevents parasite replication and clears existing infection.

Side Effects

Malarone Paediatric may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Abdominal pain: discomfort in the upper abdomen.
  • Headache: transient headache episodes.
  • Diarrhoea: loose stools, usually self‑limiting.
  • Metallic taste: temporary alteration of taste perception.
  • Rash: mild skin redness or itching.

Serious or Rare Side Effects

  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hepatotoxicity: elevated liver enzymes or jaundice.
  • Hemolytic anaemia: especially in patients with G6PD deficiency.
  • Severe hypersensitivity: anaphylaxis or angioedema.
  • Cardiac arrhythmias: rare QT prolongation.
  • Visual disturbances: blurred vision or eye pain.

Precautions & Warnings

Before prescribing Malarone Paediatric, clinicians should consider several safety aspects.

  • Weight‑based dosing: dose must be calculated according to the child's weight and age.
  • Renal or hepatic impairment: adjust therapy and monitor function closely.
  • G6PD deficiency: assess risk of hemolysis before use.
  • Concomitant QT‑prolonging drugs: avoid or monitor cardiac rhythm.
  • Pregnancy and breastfeeding: use only if benefits outweigh potential risks.
  • Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Avoid Interactions

Malarone Paediatric can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Rifampicin: reduces plasma concentrations of both components, compromising efficacy.
  • Cimetidine: may increase atovaquone levels, raising risk of toxicity.
  • Antiretroviral protease inhibitors (e.g., ritonavir): can significantly lower atovaquone exposure.

Moderate Interactions (Monitor Closely)

  • Warfarin: may enhance anticoagulant effect; monitor INR.
  • Digoxin: possible increase in serum levels; observe for toxicity.
  • Other QT‑prolonging agents: monitor ECG for arrhythmias.

Frequently Asked Questions

Malarone Paediatric is an oral antimalarial combination of atovaquone and proguanil indicated for the prevention of malaria in children traveling to endemic regions and for the treatment of acute, uncomplicated Plasmodium falciparum malaria in pediatric patients.

Atovaquone blocks the mitochondrial electron transport chain of the malaria parasite, halting energy production, while proguanil is converted to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme, disrupting folate synthesis. Together they provide a synergistic effect that both prevents infection and clears existing parasites.

The dose of Malarone Paediatric is determined by the prescribing clinician based on the child’s weight, age, and the indication (prophylaxis or treatment). The prescriber will calculate the appropriate tablet strength and dosing schedule for each individual patient.

Safety data for atovaquone/proguanil in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with older agents such as chloroquine, atovaquone/proguanil offers a broader spectrum against chloroquine‑resistant Plasmodium falciparum and has a more convenient once‑daily dosing regimen. However, it may be more expensive and requires careful attention to drug‑interaction potential.

Malarone Paediatric tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the container tightly closed and out of reach of children.

The tablets are taken orally with food or a milky drink to improve absorption. For prophylaxis, they are usually taken once daily starting 1–2 days before travel and continued for 7 days after leaving the endemic area. For treatment, the regimen follows the prescriber’s instructions.

Serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome, hepatotoxicity, hemolytic anemia in G6PD‑deficient patients, and rare cardiac arrhythmias. Immediate medical attention is required if any of these symptoms develop.

Children with known hypersensitivity to atovaquone, proguanil, or any component of the formulation should avoid the product. It is also contraindicated in patients with severe renal or hepatic impairment and in those with G6PD deficiency due to the risk of hemolysis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Proguanil Hydrochloride, Atovaquone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT